

# Noel Faux

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9381249/publications.pdf>

Version: 2024-02-01

42  
papers

3,472  
citations

236833

25  
h-index

360920

35  
g-index

47  
all docs

47  
docs citations

47  
times ranked

6026  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1318.	4.9	348
2	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 509-516.	1.2	347
3	Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. <i>Diabetes Care</i> , 2013, 36, 2981-2987.	4.3	308
4	A Common Fold Mediates Vertebrate Defense and Bacterial Attack. <i>Science</i> , 2007, 317, 1548-1551.	6.0	261
5	Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. <i>Nature Communications</i> , 2015, 6, 6760.	5.8	240
6	Functional insights from the distribution and role of homopeptide repeat-containing proteins. <i>Genome Research</i> , 2005, 15, 537-551.	2.4	189
7	GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. <i>Nature Structural and Molecular Biology</i> , 2007, 14, 280-286.	3.6	189
8	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010, 133, 3349-3358.	3.7	130
9	Plasma Amyloid- $\beta$ as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1233-1242.	1.2	122
10	Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 173-178.	0.7	115
11	An anemia of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2014, 19, 1227-1234.	4.1	114
12	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 53-61.	0.4	114
13	A blood-based predictor for neocortical A $\beta$ burden in Alzheimer's disease: results from the AIBL study. <i>Molecular Psychiatry</i> , 2014, 19, 519-526.	4.1	108
14	Associations between gonadotropins, testosterone and $\beta$ amyloid in men at risk of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2014, 19, 69-75.	4.1	98
15	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 909-922.	1.2	83
16	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 661-668.	1.2	76
17	Decreased Plasma Iron in Alzheimer's Disease Is Due to Transferrin Desaturation. <i>ACS Chemical Neuroscience</i> , 2015, 6, 398-402.	1.7	75
18	Blood-Borne Amyloid- $\beta$ Dimer Correlates with Clinical Markers of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2010, 30, 6315-6322.	1.7	70

#	ARTICLE	IF	CITATIONS
19	Cull(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. <i>Scientific Reports</i> , 2017, 7, 42292.	1.6	70
20	Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in <i>APOE</i> $\epsilon$ $\epsilon$ Carriers. <i>JAMA Neurology</i> , 2017, 74, 122.	4.5	61
21	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 171-182.	1.2	46
22	A domain level interaction network of amyloid precursor protein and $A\beta$ of Alzheimer's disease. <i>Proteomics</i> , 2010, 10, 2377-2395.	1.3	41
23	RCPdb: An evolutionary classification and codon usage database for repeat-containing proteins. <i>Genome Research</i> , 2007, 17, 1118-1127.	2.4	36
24	Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. <i>Metallomics</i> , 2016, 8, 628-632.	1.0	30
25	The matrix refolded. <i>Nature Methods</i> , 2005, 2, 3-3.	9.0	29
26	Altered transition metal homeostasis in Niemann-Pick disease, type C1. <i>Metallomics</i> , 2014, 6, 542-553.	1.0	26
27	Predicting Alzheimer disease from a blood-based biomarker profile. <i>Neurology</i> , 2016, 87, 1093-1101.	1.5	26
28	Protein Folding Database (PFD 2.0): an online environment for the International Proteomics Consortium. <i>Nucleic Acids Research</i> , 2007, 35, D304-D307.	6.5	24
29	A blood-based signature of cerebrospinal fluid $A\beta$ $_{1-42}$ status. <i>Scientific Reports</i> , 2019, 9, 4163.	1.6	21
30	Single Amino Acid and Trinucleotide Repeats. <i>Advances in Experimental Medicine and Biology</i> , 2012, 769, 26-40.	0.8	17
31	Increasing the Predictive Accuracy of Amyloid- $\beta$ Blood-Borne Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 47-59.	1.2	16
32	Peripheral $\alpha$ -Defensins 1 and 2 are Elevated in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1131-1143.	1.2	15
33	CLIMS: Crystallography Laboratory Information Management System. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 1691-1693.	2.5	9
34	Serpins in Prokaryotes. , 2007, , 131-162.		6
35	Response to Comment on Moore et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. <i>Diabetes Care</i> 2013;36:2981-2987. <i>Diabetes Care</i> , 2014, 37, e151-e151.	4.3	4
36	Managing and mining protein crystallization data. <i>Proteins: Structure, Function and Bioinformatics</i> , 2005, 62, 4-7.	1.5	3

#	ARTICLE	IF	CITATIONS
37	eResearch Solutions for High Throughput Structural Biology. , 2007, , .		2
38	High-throughput protein structure determination using grid computing. , 2009, , .		1
39	P2-326: Difference in the Rate of Cognitive Change between Individuals with and Without Vascular Risk Factors: A Longitudinal Study. , 2016, 12, P766-P767.		0
40	O5â€05â€01: CSF Ferritin Determines the Risk of Cognitive Decline in Preâ€Clinical <i>APOE</i>â€E4 Carriers. Alzheimer's and Dementia, 2016, 12, P387.	0.4	0
41	P4â€070: A BLOODâ€BASED SIGNATURE OF CEREBRAL SPINAL FLUID AÎ²<sub>1â€42</sub> STATUS. Alzheimer's and Dementia, 2018, 14, P1460.	0.4	0
42	P1â€270: THE COMBINED EFFECT OF APOE, BDNF, CSF AÎ² AND PTAU ON ALZHEIMER'S DISEASE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P385.	0.4	0